[1. Pasricha JS, Khaitan BK, Dash S. Pigmentary disorders in India. Dermatol Clin. 2007;25(3):343-52.10.1016/j.det.2007.05.00417662900]Search in Google Scholar
[2. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, et al. A global survey of the role of ultra-violet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23(11):1254-62.10.1111/j.1468-3083.2009.03295.x19486232]Search in Google Scholar
[3. Jang YH, Lee JY, Kang HY, Lee ES, Kim YC. Oestrogen and progesterone receptor expression in melasma: an immunohistochemical analysis. J Eur Acad Dermatol Venereol. 2010;24(11):1312-6.10.1111/j.1468-3083.2010.03638.x20337826]Search in Google Scholar
[4. Roberts WE. Pollution as a risk factor for the development of melasma and other skin disorders of facial hyperpigmentation - is there a case to be made? J Drugs Dermatol. 2015;14(4):337-41.]Search in Google Scholar
[5. Lee DB, Suh HS, Choi YS. A comparative study of lowfluence 1,064 nm Q-Switched Nd: YAG laser with or without chemical peeling using Jessner’s solution in melasma patients. J Cosmet Laser Ther. 2014;16(6):264-70.10.3109/14764172.2013.86420124245978]Search in Google Scholar
[6. Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q‐switched ruby laser. J Dermatol Surg Oncol. 1994;20(9):592-7.10.1111/j.1524-4725.1994.tb00152.x8089359]Search in Google Scholar
[7. Moreno Arias GA, Ferrando J. Intense pulsed light for melanocytic lesions. Dermatol Surg. 2001;27(4):397-400.10.1046/j.1524-4725.2001.00315.x11298715]Search in Google Scholar
[8. Wang CC, Hui CY, Sue YM, Wong WR, Hong HS. Intense pulsed light for the treatment of refractory melasma in Asian persons. Dermatol Surg. 2004;30(9):1196-200.10.1111/j.1524-4725.2004.30371.x]Search in Google Scholar
[9. Jutley GS, Rajaratnam R, Halpern J, Salim A, Emmett C. Systematic review of randomized controlled trials on interventions for melasma: an abridged Cochrane review. J Am Acad Dermatol. 2014;70(2):369-73.10.1016/j.jaad.2013.07.04424438951]Search in Google Scholar
[10. Chan R, Park KC, Lee MH, Lee ES, Chang SE, Leow YH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0· 01%, hydroquinone 4%, tretinoin 0· 05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159(3):697-703.10.1111/j.1365-2133.2008.08717.x]Search in Google Scholar
[11. Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther. 1996;276(2):765-9.]Search in Google Scholar
[12. Monteiro RC, Kishore BN, Bhat RM, Sukumar D, Martis J, Ganesh HK. A comparative study of the efficacy of 4% hydroquinone vs 0.75% Kojic acid cream in the treatment of facial melasma. Indian J Dermatol. 2013;58(2):157.10.4103/0019-5154.108070365722723716817]Search in Google Scholar
[13. Wu S, Shi H, Wu H, Yan S, Guo J, Sun Y, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic Plast Surg. 2012;36(4):964-70.10.1007/s00266-012-9899-922552446]Search in Google Scholar
[14. Karn D, Kc S, Amatya A, Razouria EA, Timalsina M. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J (KUMJ). 2012;10(4):40-3.10.3126/kumj.v10i4.1099323575051]Search in Google Scholar
[15. Grover C, Reddu BS. The therapeutic value of glycolic acid peels in dermatology. Indian J Dermatol Venereol Leprol. 2003;69(2):148-50.]Search in Google Scholar
[16. Kumari R, Thappa DM. Comparative study of trichloroacetic acid versus glycolic acid chemical peels in the treatment of melasma. Indian J Dermatol Venereol Leprol. 2010;76(4):447.10.4103/0378-6323.6660220657143]Search in Google Scholar
[17. Wattanakrai P, Mornchan R, Eimpunth S. Low‐fluence Q‐switched neodymium‐doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg. 2010;36(1):76-87.10.1111/j.1524-4725.2009.01383.x20298254]Search in Google Scholar
[18. Manaloto RM, Alster T. Erbium: YAG laser resurfacing for refractory melasma. Dermatol Surg. 1999;25(2):121-3.10.1046/j.1524-4725.1999.08103.x10037517]Search in Google Scholar
[19. Lee HS, Won CH, Lee DH, An JS, Chang HW, Lee JH, et al. Treatment of melasma in Asian skin using a fractional 1,550-nm laser: an open clinical study. Dermatol Surg. 2009;35(10):1499-504.10.1111/j.1524-4725.2009.01264.x19674038]Search in Google Scholar
[20. Tamega Ade A, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013;27(2):151-6.10.1111/j.1468-3083.2011.04430.x22212073]Search in Google Scholar
[21. Lutfi RJ, Fridmanis M, Misiunas AL, Pafume O, Gonzalez EA, Villemur JA, et al. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma. J Clin Endocrinol Metab. 1985;61(1):28-31.10.1210/jcem-61-1-283923030]Search in Google Scholar
[22. Zoccali G, Piccolo D, Allegra P, Giuliani M. Melasma treated with intense pulsed light. Aesthetic Plast Surg. 2010;34(4):486-93.10.1007/s00266-010-9485-y20225000]Search in Google Scholar